Skye Bioscience, Inc. — Director's Dealing 2021

Oct 6, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Skye Bioscience, Inc. (SKYE)
CIK: 0001516551
Period of Report: 2021-10-04

Reporting Person: Arsenault Kaitlyn Melanie (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.12	2031-09-14	Common Stock (400000.0)		Direct

Footnotes

F1: 10% of the Options shall vest on September 15, 2021 (the "Vesting Start Date") and the remaining 90% will vest in equal annual installments on the anniversary of the Vesting Start Date over four annual periods.